In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

Viking aims to compete against market giants Eli Lilly and Novo Nordisk in the billion-dollar weight loss drug market. The ...

A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...

Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...

Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...